In the middle of an R&D shakeup, Novartis makes a $300M investment in early-stage biologics research tech

Within the past six months, Novartis has tapped new leaders for both its research arm and development organization. But Vas Narasimhan isn’t done revamping the global R&D org.

While his previous moves involved big cuts, this time the CEO is looking to add something: a $300 million initiative to bolster Novartis’ capacity and capabilities for “early technical development of biologics.”

NIBR chief Jay Bradner joins the exodus at Novartis, handing the keys to Fiona Marshall

As Novartis experienced firsthand with the late-stage development of the PCSK9 drug inclisiran, manufacturing hiccups can lead to costly delays — and most of the earlier speed bumps largely go behind the scenes.